Use of SGLT-2 Inhibitors in Patients With Type 2 Diabetes Mellitus and Abdominal Obesity: An Asian Perspective and Expert Recommendations
At AK Twisted Wellness, we look at the full picture: your hormones, your metabolic markers, your lifestyle, and your goals before recommending any GLP 1 therapy
While WADA continues its investigation, some athletes are making their own assessments about whether to use GLP-1 agonists as part of their overall health plan
Our biggest concern was reducing those comorbidities and the long-term impact that that has on the cost of insurance in general, because more comorbidities means more claims, Arnold said, referring to diseases and conditions associated with obesity
Yes, Novo uses recombinant peptide, but their incentives and priorities are vastly different to generic pharma's
Redox control of liver function in health and disease